Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses

Science. 2019 May 10;364(6440):558-566. doi: 10.1126/science.aav7062. Epub 2019 Apr 18.

Abstract

Targeted blockade of PD-1 with immune checkpoint inhibitors can activate T cells to destroy tumors. PD-1 is believed to function mainly at the effector, but not in the activation, phase of T cell responses, yet how PD-1 function is restricted at the activation stage is currently unknown. Here we demonstrate that CD80 interacts with PD-L1 in cis on antigen-presenting cells (APCs) to disrupt PD-L1/PD-1 binding. Subsequently, PD-L1 cannot engage PD-1 to inhibit T cell activation when APCs express substantial amounts of CD80. In knock-in mice in which cis-PD-L1/CD80 interactions do not occur, tumor immunity and autoimmune responses were greatly attenuated by PD-1. These findings indicate that CD80 on APCs limits the PD-1 coinhibitory signal, while promoting CD28-mediated costimulation, and highlight critical components for induction of optimal immune responses.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Autoimmunity
  • B7-1 Antigen / genetics
  • B7-1 Antigen / metabolism*
  • B7-H1 Antigen / metabolism*
  • CD28 Antigens / metabolism
  • Dendritic Cells / immunology
  • Gene Knock-In Techniques
  • Humans
  • Immunotherapy
  • Lymphocyte Activation
  • Mice
  • Mice, Mutant Strains
  • Neoplasms / immunology*
  • Neoplasms / therapy
  • Programmed Cell Death 1 Receptor / metabolism*
  • Protein Binding
  • T-Lymphocytes / immunology*

Substances

  • B7-1 Antigen
  • B7-H1 Antigen
  • CD28 Antigens
  • Programmed Cell Death 1 Receptor